注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Aldeyra Therapeutics Inc是一家生物技術公司,致力於開發免疫調節療法來治療眼部和全身性疾病。該公司的主要候選產品reproxalap是一種治療乾眼病(DED)和過敏性結膜炎(AC)的後期開發藥物。該公司還有其他正在開發中的候選產品,這些產品用於治療增殖性玻璃體視網膜病變(PVR)、原發性玻璃體視網膜淋巴瘤(PVRL)和其他視網膜疾病、自身免疫性疾病和癌症。該公司的產品開發管線專注於免疫介導的眼部疾病和選擇全身性疾病,包括兩種生物學作用機制:活性醛類(RASP)調節和二氫葉酸還原酶抑制。其候選產品的免疫活性通常通過下調免疫細胞激活或增殖引起病理炎症水平降低。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Ben R. Bronstein | 71 | 2010 | Independent Director |
Martin J. Joyce | 67 | 2013 | Independent Director |
Paul M. Karpecki | 54 | 2020 | Member of Anterior Segment Scientific Advisory Board |
Gary M. Phillips | 55 | 2009 | Independent Director |
Richard Huntington Douglas | 68 | 2016 | Independent Chair of the Board |
Todd C. Brady | 49 | 2005 | CEO, President & Director |
David Chu | - | - | Member of Anterior Segment Scientific Advisory Board |
Nancy Miller-Rich | 62 | 2020 | Independent Director |
Neal S. Walker | 51 | 2013 | Independent Director |
John J. Sheppard | - | - | Member of Anterior Segment Scientific Advisory Board |
Jay S. Duker | 63 | - | Member of Retina Segment Scientific Advisory Board |
Dean Eliott | - | - | Member of Retina Segment Scientific Advisory Board |
Jeffrey S. Heier | 61 | - | Member of Retina Segment Scientific Advisory Board |
Quan Dong Nguyen | - | - | Member of Retina Segment Scientific Advisory Board |
Carl D. Regillo | - | - | Member of Retina Segment Scientific Advisory Board |
Victor Perez | - | - | Member of Anterior Segment Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核